ALK and poorly differentiated thyroid gland carcinoma: Case Report: Lorlatinib for the treatment of &lt;i&gt;ALK&lt;/i&gt;-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor.